Strides Arcolab announced that it has entered into a licensing agreement with Gilead Sciences Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs. The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV. As part of the licensing agreement, pending US Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
69.96 USD | -0.01% | +4.90% | -13.64% |
Jul. 11 | Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 | MT |
Jul. 09 | RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.64% | 87.16B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Strides Arcolab Inks Agreement with Gilead Sciences, Inc. to Manufacture and Distribute TAF